Brokerages Set Artivion, Inc. (NYSE:AORT) PT at $49.11

Artivion, Inc. (NYSE:AORT) has received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $49.1143.

AORT has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, October 8th. Canaccord Genuity Group restated a “buy” rating and issued a $51.00 target price on shares of Artivion in a research note on Wednesday, December 17th. JMP Securities increased their price target on Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a research report on Friday, October 10th. Needham & Company LLC raised their price target on Artivion from $50.00 to $58.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Finally, Citizens Jmp boosted their price objective on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th.

Artivion Stock Performance

AORT stock opened at $42.59 on Monday. The company has a current ratio of 3.93, a quick ratio of 2.88 and a debt-to-equity ratio of 0.50. The firm has a market cap of $2.02 billion, a P/E ratio of -177.45 and a beta of 1.59. Artivion has a 12-month low of $21.97 and a 12-month high of $48.25. The stock’s 50 day simple moving average is $45.50 and its 200 day simple moving average is $41.28.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. The firm had revenue of $113.39 million during the quarter, compared to the consensus estimate of $110.71 million. Artivion had a negative net margin of 2.16% and a positive return on equity of 5.98%. The business’s quarterly revenue was up 18.9% on a year-over-year basis. As a group, equities research analysts predict that Artivion will post 0.37 EPS for the current year.

Insider Activity

In related news, insider John E. Davis sold 6,563 shares of the stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $45.86, for a total value of $300,979.18. Following the sale, the insider owned 198,842 shares of the company’s stock, valued at $9,118,894.12. This trade represents a 3.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Marshall S. Stanton sold 47,376 shares of the business’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $45.04, for a total transaction of $2,133,815.04. Following the transaction, the senior vice president directly owned 44,753 shares of the company’s stock, valued at $2,015,675.12. The trade was a 51.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 234,511 shares of company stock worth $10,612,452. 7.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Artivion

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd increased its stake in Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after acquiring an additional 519 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of Artivion in the 3rd quarter worth approximately $27,000. Smartleaf Asset Management LLC grew its holdings in shares of Artivion by 47.7% during the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after purchasing an additional 538 shares in the last quarter. USA Financial Formulas grew its holdings in shares of Artivion by 163.5% during the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after purchasing an additional 703 shares in the last quarter. Finally, State of Wyoming bought a new stake in shares of Artivion during the third quarter valued at approximately $80,000. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.